These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 11665724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
    Brenner MA, Harkless LB, Mendicino RW, Page JC.
    J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
    Shemer A, Nathansohn N, Trau H, Amichai B, Grunwald MH.
    J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
    Paul C, Coustou D, Lahfa M, Bulai-Livideanu C, Doss N, Mokthar I, Turki H, Nouira R, Fazaa B, Ben Osman A, Zourabichvili O, Cazeau C, Coubetergues H, Picot S, Bienvenu AL, Voisard JJ.
    Dermatology; 2013 Feb; 227(2):157-64. PubMed ID: 24051622
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ciclopirox nail lacquer topical solution 8%.
    Gupta AK.
    Skin Therapy Lett; 2000 Feb; 6(1):1-5. PubMed ID: 11027420
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
    Schalka S, Nunes S, Gomes Neto A.
    An Bras Dermatol; 2012 Feb; 87(1):19-25. PubMed ID: 22481647
    [Abstract] [Full Text] [Related]

  • 12. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
    Avner S, Nir N, Henri T.
    J Dermatolog Treat; 2005 Feb; 16(5-6):327-30. PubMed ID: 16428154
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
    Galitz J.
    Cutis; 2001 Aug; 68(2 Suppl):23-4. PubMed ID: 11665725
    [Abstract] [Full Text] [Related]

  • 17. [Therapy with ciclopirox lacquer of onychomycoses caused by molds].
    Ulbricht H, Wörz K.
    Mycoses; 1994 Aug; 37 Suppl 1():97-100. PubMed ID: 7854374
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A-Detail fact sheet (Canada). Ciclopirox 8% nail lacquer (Penlac).
    Skin Therapy Lett; 1994 Aug; 10(10):suppl 1 p.. PubMed ID: 16518906
    [No Abstract] [Full Text] [Related]

  • 20. Development of ciclopirox nail lacquer with enhanced permeation and retention.
    Thapa RK, Choi JY, Go TG, Kang MH, Han SD, Jun JH, Son MW, Yong CS, Kim JO.
    Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.